Annexon Earnings Reports

Annexon reported its Q4 and full year 2024 financial results, highlighting the progress of its portfolio, especially the ANX005, ANX007, and ANX1502 programs. The company's cash, cash equivalents, and short-term investments totaled approximately $312 million as of December 31, 2024, expected to fund operations into the second half of 2026.

Annexon's third quarter 2024 results highlighted the company's progress in its clinical programs, including ANX005, ANX007, and ANX1502. The company's cash, cash equivalents, and short-term investments totaled $340.1 million as of September 30, 2024, which is expected to fund operations into the second half of 2026.

Annexon reported a net loss of $29.6 million, or $0.23 per share, for the quarter ended June 30, 2024. The company's cash, cash equivalents, and short-term investments totaled $368.7 million as of June 30, 2024, which is expected to fund operations into the second half of 2026.

Annexon reported a net loss of $25.2 million for the first quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $264.9 million as of March 31, 2024, expected to fund operations into mid-2026. The company is advancing its clinical programs, including ANX005 in GBS, ANX007 in GA, and ANX1502 for autoimmune conditions.

Annexon reported a net loss of $27.9 million for the quarter ended December 31, 2023. The company's cash, cash equivalents, and short-term investments totaled approximately $260 million as of December 31, 2023, providing an anticipated runway into mid-2026. Key milestones include the expected pivotal Phase 3 data for ANX005 in Guillain-Barré Syndrome (GBS) in the second quarter of 2024 and the planned initiation of the pivotal Phase 3 ANX007 ARCHER II trial in Geographic Atrophy (GA) in mid-2024.

Annexon reported a net loss of $32.5 million for the third quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $165.3 million as of September 30, 2023, which is expected to fund operations into the second quarter of 2025. The company is prioritizing ANX005 for GBS, ANX007 for GA and ANX1502.

Annexon reported a net loss of $35.2 million for the second quarter of 2023. The company's cash and cash equivalents were $192.9 million as of June 30, 2023, which is expected to fund operations into 2025. The company is focused on advancing its clinical-stage portfolio of medicines.

Annexon reported a net loss of $38.7 million, or $0.52 per share, for the first quarter of 2023. The company's cash and cash equivalents were $228.2 million as of March 31, 2023, which is expected to fund operations into 2025.

Annexon reported a net loss of $34.4 million for the quarter ended December 31, 2022, and cash and cash equivalents and short-term investments were $242.7 million as of December 31, 2022.

Annexon reported a net loss of $35.1 million, or $0.51 per share, for the third quarter of 2022. The company's cash and cash equivalents were $269.5 million as of September 30, 2022, which is expected to fund operations into the second half of 2025.

Annexon reported a net loss of $37.1 million, or $0.96 per share, for the quarter ended June 30, 2022. The company's cash and cash equivalents were $177.6 million as of June 30, 2022, and with the proceeds from a recent financing, they expect to fund operations into the second half of 2025.

Annexon reported a net loss of $35.4 million for the quarter ended March 31, 2022. The company's cash and cash equivalents were $206.7 million as of March 31, 2022, which is expected to fund operating plans into 2024. The company anticipates eight clinical catalysts across its pipeline throughout 2022 and 2023.

Annexon reported a net loss of $37.4 million for the fourth quarter of 2021. The company's cash and cash equivalents and short-term investments were $242.7 million as of December 31, 2021, expected to fund operating plans into the first quarter of 2024. The company is advancing its pipeline across three therapeutic franchises, with numerous clinical data readouts and new study initiations anticipated over the course of 2022 and 2023.

Annexon reported a net loss of $35.6 million for the third quarter of 2021. The company's cash and cash equivalents and short-term investments were $271.4 million as of September 30, 2021, which is expected to fund operating plans into 2024.

Annexon reported a net loss of $31.3 million for the second quarter of 2021, with research and development expenses at $24.6 million and general and administrative expenses at $6.8 million. Cash and cash equivalents totaled $302.4 million as of June 30, 2021.

Annexon's cash and cash equivalents and short-term investments were $326.7 million as of March 31, 2021. Research and development expenses were $20.7 million for the quarter ended March 31, 2021. Net loss was $26.0 million for the quarter ended March 31, 2021.

Annexon reported a net loss of $23.2 million for the quarter ended December 31, 2020, compared to a net loss of $8.9 million for the quarter ended December 31, 2019. The company's cash and cash equivalents and short-term investments were $351.2 million as of December 31, 2020.

Annexon reported a net loss of $15.6 million for the third quarter of 2020. The company's cash and cash equivalents totaled $370.7 million as of September 30, 2020, bolstered by the July IPO.

Annexon reported second quarter results, highlighting the completion of a $263M IPO in July and plans to initiate four new clinical trials by year-end. Cash and cash equivalents were $124.8 million as of June 30, 2020. Net loss attributable to common stockholders was $12.5 million or $28.87 per share for the quarter ended June 30, 2020.